Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 3/2018

18.07.2018 | Neurogenic Bladder (C Powell, Section Editor)

The Role of Chemical Sphincterotomy with Urethral Botulinum Toxin Injection in Patients with Neurogenic and Non-neurogenic Failure to Empty

verfasst von: William R. Boysen, Gregory T. Bales

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review focuses on the evidence for injection of botulinum A toxin (BTX) to the external urinary sphincter for management of impaired bladder emptying secondary to neurogenic conditions such as detrusor sphincter dyssynergia (DSD) and non-neurogenic conditions such as dysfunctional voiding (DV). The application of urethral BTX for patients with impaired emptying secondary to detrusor underactivity will also be discussed. The goal of the review is to comprehensively analyze the evidence surrounding urethral BTX in this context and help guide decision-making.

Recent Findings

A robust body of literature including case series, a randomized control trial (RCT), and a meta-analysis support the use of urethral BTX for the treatment of DSD in spinal cord injury (SCI) patients, with documented improvement in urethral pressure and post-void residual urine volume (PVR). A second RCT among patients with DSD and MS demonstrated no improvement in urethral pressure, PVR, or maximum urine flow rate following urethral BTX relative to control. For non-neurogenic conditions like DV and pelvic floor spasticity, there are mixed data regarding the efficacy of urethral BTX. Small series have reported improvement in PVR and urethral pressure, but a RCT in this patient population demonstrated no benefit of urethral BTX relative to control.

Summary

Urethral BTX effectively lowers urethral pressure and PVR in SCI patients with DSD, though the long-term impact on renal function requires further study. For patients with MS and those with non-neurogenic conditions like DV, pelvic floor spasticity, and detrusor under activity, the role of urethral BTX is not well defined. Further study in these patient populations should be undertaken prior to widespread utilization.
Literatur
1.
Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107(3):458–61.CrossRefPubMed
2.
Ross JC, Damanski M, Gibbon N. Resection of the external urethral sphincter in the paraplegic; preliminary report. J Urol. 1958 Apr;79(4):742–6.CrossRefPubMed
3.
• Moore D, Cohn J, Dmochowski R. Use of botulinum toxin A in the treatment of lower urinary tract disorders: a review of the literature. Toxins. 2016;8(4):88. This thorough and detailed review article provides an overview of the mechanism of action of botulinum toxin and applications in the lower urinary tract CrossRefPubMedPubMedCentral
4.
Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003 Aug;44(2):165–74.CrossRefPubMed
5.
Cruz F. Targets for botulinum toxin in the lower urinary tract: targets for botulinum toxin. Neurourol Urodyn. 2014 Jan;33(1):31–8.CrossRefPubMed
6.
Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996 Mar;155(3):1023–9.CrossRefPubMed
7.
•• Mehta S, Hill D, Foley N, Hsieh J, Ethans K, Potter P, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93(4):597–603. This meta-analysis pools all available data on urethral botulinum toxin in the spinal cord injury patient population, providing the highest level of evidence available for this clinical application. CrossRefPubMed
8.
Kuo H-C. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003;61(3):550–4.CrossRefPubMed
9.
Kuo H-C. Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction. Tzu Chi Med J. 2016;28(3):89–93.CrossRef
10.
Tsai S-J, Ying T-H, Huang Y-H, Cheng J-W, Bih L-I, Lew HL. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009 May;90(5):832–6.CrossRefPubMed
11.
Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988 May;139(5):919–22.CrossRefPubMed
12.
Soler JM, Previnaire JG, Hadiji N. Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury. Spinal Cord. 2016 Jun;54(6):452–6.CrossRefPubMed
13.
Kuo H-C. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn. 2008 Nov;27(8):793–6.CrossRefPubMed
14.
de Sèze M, Petit H, Gallien P, de Sèze M-P, Joseph P-A, Mazaux J-M, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002 Jul;42(1):56–62.CrossRefPubMed
15.
• Gallien P. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670–6. This randomized control trial assessed urethral botulinum toxin for treating DSD in patients with MS found no benefit to treatment, raising doubts regarding the use of urethral BTX in MS patients. CrossRefPubMedPubMedCentral
16.
Wein A, Barrett DM. Etiologic possibilities for increased pelvic floor electromyography activity during cystometry. J Urol. 1982;127(5):949–51.CrossRefPubMed
17.
Chen YH, Kuo H-C. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol Int. 2004;73(2):156–62.CrossRefPubMed
18.
•• Mangera A, Andersson K-E, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60(4):784–95. This systematic review article provides an overview of the efficacy of botulinum toxin in the lower urinary tract, including urethral BTX, with detailed complication data. CrossRefPubMed
19.
Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65(1):37–41.CrossRefPubMed
20.
Liao Y-M, Kuo H-C. Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology. 2007;70(4):763–6.CrossRefPubMed
21.
Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001;165(4):1107–10.CrossRefPubMed
22.
Mokhless I, Gaafar S, Fouda K, Shafik M, Assem A. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder. J Urol. 2006 Oct;176((4):1767–70.CrossRef
23.
Kuo H-C. Recovery of detrusor function after urethral botulinum a toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology. 2007 Jan;69(1):57–61.CrossRefPubMed
24.
• Jiang Y-H, Wang C-C, Kuo H-C. OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction—a randomized, double-blind, placebo-controlled study. Sci Rep [Internet]. 2016 Dec [cited 2018 Apr 17];6(1). Available from: http://​www.​nature.​com/​articles/​srep38905. This randomized control trial demonstrates no benefit of urethral BTX compared to placebo in treatment of non-neurogenic patients, raising doubts about the application urethral BTX to this patient population.
25.
Chancellor MB, Bennett C, Simoneau AR, Finocchiaro MV, Kline C, Bennett JK, et al. Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial. J Urol. 1999;161(6):1893–8.CrossRefPubMed
26.
Gajewski JB, Chancellor MB, Ackman CF, Appell RA, Bennett J, Binard J, et al. Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. J Urol. 2000;163(3):773–6.CrossRefPubMed
27.
Wilson TS, Lemack GE, Dmochowski RR. UroLume stents: lessons learned. J Urol. 2002;167(6):2477–80.CrossRefPubMed
28.
Hamid R, Arya M, Wood S, Patel HRH, Shah PJR. The use of the Memokath™ stent in the treatment of detrusor sphincter dyssynergia in spinal cord injury patients: a single-centre seven-year experience. Eur Urol. 2003;43(5):539–43.CrossRefPubMed
29.
Minardi D, d’Anzeo G, Parri G, Polito M, Piergallina M, El Asmar Z, et al. The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a randomized controlled prospective study. Urology. 2010;75(6):1299–304.CrossRefPubMed
30.
Datta SN, Chaliha C, Singh A, Gonzales G, Mishra VC, Kavia RBC, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int. 2008;101(2):192–6.PubMed
31.
Jonas U, Fowler CJ, Chancellor MB, Elhilali MM, Fall M, Gajewski JB, et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol. 2001 Jan;165(1):15–9.CrossRefPubMed
Metadaten
Titel
The Role of Chemical Sphincterotomy with Urethral Botulinum Toxin Injection in Patients with Neurogenic and Non-neurogenic Failure to Empty
verfasst von
William R. Boysen
Gregory T. Bales
Publikationsdatum
18.07.2018
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 3/2018
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-018-0478-z

Weitere Artikel der Ausgabe 3/2018

Current Bladder Dysfunction Reports 3/2018 Zur Ausgabe

Overactive Bladder and Lower Urinary Tract Symptoms (U Lee and S Adelstein, Section Editors)

Managing of Lower Urinary Tract Dysfunction Following Stroke

Stress Incontinence and Prolapse (S Reynolds, Section Editor)

Management of Recurrent Stress Urinary Incontinence After Failed Mid-Urethral Sling Placement

Stress Incontinence and Prolapse (S Reynolds, Section Editor)

Stress Urinary Incontinence Management in the Patient With Overactive Bladder

Overactive Bladder and Lower Urinary Tract Symptoms (U Lee and S Adelstein, Section Editors)

New Concepts in Bladder Sensation and Urinary Urgency

Overactive Bladder and Lower Urinary Tract Symptoms (U Lee and S Adelstein, Section Editors)

Ketamine-Associated Bladder Dysfunction—a Review of the Literature

Overactive Bladder and Lower Urinary Tract Symptoms (U Lee and S Adelstein, Section Editors)

Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory Urgency Urinary Incontinence)?

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise